Serial Number | 88424870 |
Word Mark | CERECOR |
Filing Date | Friday, May 10, 2019 |
Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
Status Date | Monday, July 4, 2022 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | Tuesday, October 8, 2019 |
Goods and Services | Pharmaceutical preparations for the prevention and treatment of disorders and diseases in or affecting the central nervous system; Pharmaceutical preparations for the treatment of the brain, central nervous system, and psychiatric and neurological diseases and disorders; Pharmaceutical preparations and substances for the prevention and treatment of major depressive disorder, mood disorder, psychosis, anxiety, epilepsy, sclerosis, porphyries, stroke, Huntington's disease, insomnia, Parkinson's disease, cognitive impairment; Pharmaceutical preparations for the treatment of ectoparasites, such as head lice; Steroids; Pharmaceutical preparations containing prednisolone for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculoskeletal system, the genitourinary system; Pharmaceutical preparations containing prednisolone for the treatment of inflammatory disorders; Pharmaceutical preparations containing prednisolone for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Medical delivery apparatus, namely, a valved holding chamber sold empty for use with metered dose inhalers; Cephalosporins; Antibiotics; Pharmaceutical preparations for the treatment of reflux, esophagitis, GERD (Gastro-Esophageal Reflux Disease), dyspepsia, heartburn, acid regurgitation, pyrosis, epigastric pain, irritative cough and dysphonia; Oral modified release, extended release, and/or sustained release pharmaceutical preparations for the drug carbinoxamine, a pharmaceutically acceptable salt thereof and/or carbinoxamine polistirex, intended for the treatment of seasonal and perennial allergic rhinitis, and other approved uses; Vitamin, mineral and fluoride preparations for human medical or nutritional uses; Nutritional preparation in the nature of nutritional supplement containing vitamins and fluoride; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulation of D-galactose for the treatment of phosphoglucomutase 1 (PGM1) deficiency (PGM1-CDG), oral formulation of D-mannose for the treatment of Mannose Phosphate Isomerase (MPI) deficiency (MPI-CDG), oral formulation of L-fucose for the treatment of Leukocyte Adhesion Deficiency Type II (LADII) (SLC35C1-CDG), nucleotide prodrug for the treatment of Deoxyguanosine Kinase (DGUOK) deficiency; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulations for the treatment of congenital disorders of glycosylation; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral nucleotide replacements for the treatment of Myelodysplastic Syndromes; Pharmaceutical preparations and substances for the treatment of neurogenic orthostatic hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy, and Pure Autonomic Failure; Transmembrane AMPA receptor regulatory proteins (TARPs) for use as anticonvulsant agents and to modulate neurotransmission in patients with epilepsy; Oral neuro-selective adjunctive medications; Selective kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD) and for substance use disorders |
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Saturday, May 25, 2019 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | AVALO THERAPEUTICS, INC. |
Party Type | 21 - New Owner After Publication |
Legal Entity Type | 03 - Corporation |
Address | WAYNE, PA 19087 |
Party Name | Cerecor Inc. |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 03 - Corporation |
Address | Englewood, CO 80112 |
Party Name | Cerecor Inc. |
Party Type | 10 - Original Applicant |
Legal Entity Type | 03 - Corporation |
Address | Rockville, MD 20850 |
Event Date | Event Description |
Tuesday, July 5, 2022 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
Monday, July 4, 2022 | ABANDONMENT - NO USE STATEMENT FILED |
Friday, December 3, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Wednesday, December 1, 2021 | SOU EXTENSION 4 GRANTED |
Wednesday, December 1, 2021 | SOU EXTENSION 4 FILED |
Wednesday, December 1, 2021 | TEAS EXTENSION RECEIVED |
Wednesday, September 22, 2021 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
Saturday, May 22, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Thursday, May 20, 2021 | SOU EXTENSION 3 GRANTED |
Thursday, May 20, 2021 | SOU EXTENSION 3 FILED |
Thursday, May 20, 2021 | TEAS EXTENSION RECEIVED |
Tuesday, December 8, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Monday, December 7, 2020 | SOU EXTENSION 2 GRANTED |
Wednesday, December 2, 2020 | SOU EXTENSION 2 FILED |
Wednesday, December 2, 2020 | TEAS EXTENSION RECEIVED |
Friday, June 5, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Wednesday, June 3, 2020 | SOU EXTENSION 1 GRANTED |
Wednesday, June 3, 2020 | SOU EXTENSION 1 FILED |
Wednesday, June 3, 2020 | TEAS EXTENSION RECEIVED |
Tuesday, June 2, 2020 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
Tuesday, June 2, 2020 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Tuesday, June 2, 2020 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Tuesday, June 2, 2020 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Tuesday, June 2, 2020 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
Tuesday, June 2, 2020 | WITHDRAWAL OF ATTORNEY GRANTED |
Tuesday, June 2, 2020 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED |
Wednesday, May 27, 2020 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
Wednesday, May 27, 2020 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Tuesday, April 28, 2020 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
Tuesday, April 28, 2020 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Tuesday, April 28, 2020 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
Tuesday, April 28, 2020 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Tuesday, April 28, 2020 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Tuesday, April 28, 2020 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
Tuesday, December 3, 2019 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Tuesday, October 8, 2019 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Tuesday, October 8, 2019 | PUBLISHED FOR OPPOSITION |
Wednesday, September 18, 2019 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Thursday, September 5, 2019 | ASSIGNED TO LIE |
Monday, September 2, 2019 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Friday, August 30, 2019 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Friday, August 30, 2019 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Friday, August 30, 2019 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Thursday, August 1, 2019 | NOTIFICATION OF PRIORITY ACTION E-MAILED |
Thursday, August 1, 2019 | PRIORITY ACTION E-MAILED |
Thursday, August 1, 2019 | PRIORITY ACTION WRITTEN |
Thursday, July 25, 2019 | ASSIGNED TO EXAMINER |
Saturday, May 25, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
Tuesday, May 14, 2019 | NEW APPLICATION ENTERED IN TRAM |